Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · IEX Real-Time Price · USD
53.75
+0.45 (0.84%)
May 16, 2024, 4:00 PM EDT - Market closed
Apogee Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
3.15B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPGE News
- 1 day ago - Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases - GlobeNewsWire
- 3 days ago - Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 10 days ago - Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire